세계 세팔로스포린 시장 : 세대별, 유형별, 투여 경로별, 유통 채널별, 제형별, 용도별, 최종사용자별 및 지역별(-2030년)

According to Stratistics MRC, the Global Cephalosporin Market is accounted for $16.00 billion in 2023 and is expected to reach $22.97 billion by 2030 growing at a CAGR of 5.3% during the forecast period. Cephalosporin is a bactericidal, broad-spectrum, B-lactam antibiotic that was originally developed from the fungus Acremonium. It is used to treat bacterial diseases such as tonsillitis, bronchitis, otitis media, gonorrhoea, and pneumonia, as well as skin infections, strep throat, staph infections, and others. It inhibits enzymes in the cell wall of the susceptible bacteria and disrupts cell synthesis. Cephalosporin is primarily designated for prophylaxis as well as the treatment of infections caused by bacteria.

According to the 2017 Global Impact of Respiratory Disease report, lower respiratory tract infection and pneumonia are two of the leading causes of death, accounting for approximately 4 million deaths each year. In addition, pneumonia killed 920,136 children under the age of five in 2015, accounting for 15% of all deaths in this age group. Streptococcus pneumonia is still the most common bacterial cause of pneumonia in children under the age of five, affecting 393,000 children in 2015.

Market Dynamics:

Driver:

Rising prevalence of infectious diseases

Cephalosporins are a class of antibiotics that are widely used to treat a variety of bacterial infections. The increase in infectious diseases can be attributed to various factors. One of the main drivers is the emergence of drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamase (ESBL)-producing bacteria. These resistant strains are more difficult to treat with traditional antibiotics, leading to a higher demand for cephalosporins, which are still effective against many of these bacteria. Additionally, factors such as population growth, urbanisation, and increased travel have contributed to the spread of infectious diseases. As more people live in close proximity to each other and travel frequently, the risk of infection transmission is heightened. This has led to a competitive market landscape, with a wide range of cephalosporin products available to healthcare providers.

Restraint:

High cost

The high cost of cephalosporin antibiotics poses a significant restraint on the market. Cephalosporins are often priced at a premium due to the complex manufacturing processes involved, research and development expenses, and the need for stringent quality control measures. These higher costs can limit access to these vital antibiotics, especially in low-income regions or areas with limited healthcare budgets. Additionally, the high cost of cephalosporins can put a strain on healthcare systems and lead to increased healthcare expenditures. Thus, this factor is hampering market growth.

Opportunity:

Increasing applications in various medical sectors

Expanding applications of cephalosporins beyond their traditional uses presents a significant opportunity in various medical sectors. Cephalosporins, known for their antimicrobial properties, are finding increased utility in diverse domains, including veterinary medicine, agriculture, and non-clinical settings. In veterinary medicine, cephalosporins are used to treat bacterial infections in animals, addressing concerns about animal health and the potential transfer of antibiotic-resistant bacteria to humans. In agriculture, cephalosporins are being explored for their potential to prevent and treat bacterial infections in crops and livestock. These applications aim to improve agricultural productivity and ensure food safety by controlling bacterial diseases in plants and animals. Additionally, cephalosporins are being researched for non-clinical purposes, such as in microbial synthesis processes and laboratory research, showcasing the versatility of this antibiotic class beyond conventional therapeutic use. These different domains are propelling market expansion.

Threat:

Lack of skilled professionals

The cephalosporin market faces a significant threat due to a lack of skilled professionals. Cephalosporin antibiotics require expertise in their production, quality control, and administration. However, there is a shortage of professionals with the necessary skills and knowledge to handle these tasks. This shortage can impact the overall productivity and efficiency of the market, leading to potential delays in drug development, manufacturing, and distribution. Additionally, it may limit the capacity to meet the growing demand for cephalosporin antibiotics, especially in regions where the prevalence of infectious diseases is high. Therefore, it is a significant barrier to market demand.

COVID-19 Impact

The COVID-19 virus outbreak has had a significant negative influence on the cephalosporin market. Lockdowns, travel restrictions, and business closures brought on by COVID-19 have had an impact on the economies and sectors of numerous nations. The closing of numerous plants and factories has had a detrimental influence on the production, delivery schedules, and sales of goods on the international market. A few businesses have already warned of potential delivery delays and declines in future product sales. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths.

The Respiratory Tract Infection segment is expected to be the largest during the forecast period

The Respiratory Tract Infection (RTI) segment is estimated to hold the largest share, owing to the increasing prevalence of respiratory infections globally. Cephalosporins, a class of antibiotics, are widely prescribed for treating RTIs, including pneumonia, bronchitis, and sinusitis. Their effectiveness against a broad spectrum of bacteria, including common respiratory pathogens like Streptococcus pneumoniae and Haemophilus influenzae, makes them a primary choice for clinicians. Additionally, the emergence of drug-resistant bacterial strains further emphasises the importance of cephalosporins in managing these infections. This ongoing effort is expected to sustain the growth of the RTI segment

The First-generation Cephalosporin segment is expected to have the highest CAGR during the forecast period

The First-generation Cephalosporin segment is anticipated to have lucrative growth during the forecast period. These antibiotics belong to the earliest generation of cephalosporins and have a broad spectrum of activity against gramme-positive bacteria, including staphylococci and streptococci. They are often used to treat common infections like skin and soft tissue infections, urinary tract infections, and respiratory tract infections. Moreover, healthcare professionals value first-generation cephalosporins for their efficacy, relatively low cost, and proven safety profile. Their longstanding presence in the market and established track record make them a trusted choice, especially for uncomplicated infections. Therefore, there is an increasing demand for segment growth.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. The Asia-Pacific region is a vital player in the global cephalosporin market. Cephalosporins, being a crucial class of antibiotics, are widely used in the region for treating various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. Furthermore, countries like China, India, Japan, South Korea, and others in Southeast Asia have a well-established pharmaceutical industry and are actively involved in research and development to innovate and produce cephalosporin drugs efficiently. The region's economic growth and increasing healthcare expenditure further drive the demand for cephalosporin antibiotics, ensuring a robust and promising market outlook.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. The North American region holds a prominent position in the global cephalosporin market, being a key hub for pharmaceutical advancements and healthcare infrastructure. The market's growth is propelled by factors such as the increasing prevalence of bacterial infections, a growing elderly population prone to infections, and a high demand for efficient healthcare solutions. Furthermore, countries like the United States and Canada drive the cephalosporin market in North America. These nations have well-established pharmaceutical manufacturing capabilities and robust research and development efforts aimed at innovation and drug discovery.

Key players in the market

Some of the key players in the Cephalosporin Market include: F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Novartis AG, GlaxoSmithKline plc, Merck & Co., Inc., AstraZeneca, Aurobindo Pharma, Johnson & Johnson Private Limited, Cipla Inc., Sun Pharmaceutical Industries Ltd., Currax Pharmaceuticals LLC, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Aristo Pharmaceuticals Ltd, Baxter International, Lupin Pharmaceuticals Inc., Mankind Pharma and Macleods Pharmaceuticals Ltd.

Key Developments:

In September 2023, Major Cipla has announced that it acquires South Africa wholly-owned subsidiary of the Mumbai-based drug major, has inked a binding term sheet with Actor Holdings (Pty) Ltd to acquire 100 per cent of the issued ordinary shares of Actor Pharma, the drug major said in a regulatory filing. This development underpins Cipla's commitment and investment in its over-the- counter (OTC) business and supports its journey to be a leading healthcare player in South Africa.

In April 2023, Cipla signs pact with Novartis Pharma AG for diabetes drug Galvus. The perpetual license agreement is to manufacture and market the drug and its combination brands from January 2026. The agreement is subject to satisfaction of certain conditions precedent. During the interim Cipla will continue to market and distribute Galvus branded products. This deal is expected to further bolster Cipla's position in India as one of the top players in the diabetes category.

Generations Covered:

• First-generation Cephalosporin
• Second-generation Cephalosporin
• Third-generation Cephalosporin
• Fourth-generation Cephalosporin
• Fifth-generation Cephalosporin

Types Covered:

• Branded
• Generic

Route of Administrations Covered:

• Intravenous
• Oral

Distribution Channels Covered:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Dosage Forms Covered:

• Capsules
• Tablets
• Other Dosage Forms

Applications Covered:

• Respiratory Tract Infection
• Ear Infection
• Sexually Transmitted Infection
• Skin Infection
• Urinary Tract Infection
• Other Applications

End Users Covered:

• Hospitals
• Specialty Clinics
• Homecare
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Cephalosporin Market, By Generation

• 5.1 Introduction
• 5.2 First-generation Cephalosporin
• 5.3 Second-generation Cephalosporin
• 5.4 Third-generation Cephalosporin
• 5.5 Fourth-generation Cephalosporin
• 5.6 Fifth-generation Cephalosporin

6 Global Cephalosporin Market, By Type

• 6.1 Introduction
• 6.2 Branded
• 6.3 Generic

7 Global Cephalosporin Market, By Route of Administration

• 7.1 Introduction
• 7.2 Intravenous
• 7.3 Oral

8 Global Cephalosporin Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Hospital Pharmacy
• 8.3 Retail Pharmacy
• 8.4 Online Pharmacy

9 Global Cephalosporin Market, By Dosage Form

• 9.1 Introduction
• 9.2 Capsules
• 9.3 Tablets
• 9.4 Other Dosage Forms

10 Global Cephalosporin Market, By Application

• 10.1 Introduction
• 10.2 Respiratory Tract Infection
• 10.3 Ear Infection
• 10.4 Sexually Transmitted Infection
• 10.5 Skin Infection
• 10.6 Urinary Tract Infection
• 10.7 Other Applications

11 Global Cephalosporin Market, By End User

• 11.1 Introduction
• 11.2 Hospitals
• 11.3 Specialty Clinics
• 11.4 Homecare
• 11.5 Other End Users

12 Global Cephalosporin Market, By Geography

• 12.1 Introduction
• 12.2 North America
  • 12.2.1 US
  • 12.2.2 Canada
  • 12.2.3 Mexico
• 12.3 Europe
  • 12.3.1 Germany
  • 12.3.2 UK
  • 12.3.3 Italy
  • 12.3.4 France
  • 12.3.5 Spain
  • 12.3.6 Rest of Europe
• 12.4 Asia Pacific
  • 12.4.1 Japan
  • 12.4.2 China
  • 12.4.3 India
  • 12.4.4 Australia
  • 12.4.5 New Zealand
  • 12.4.6 South Korea
  • 12.4.7 Rest of Asia Pacific
• 12.5 South America
  • 12.5.1 Argentina
  • 12.5.2 Brazil
  • 12.5.3 Chile
  • 12.5.4 Rest of South America
• 12.6 Middle East & Africa
  • 12.6.1 Saudi Arabia
  • 12.6.2 UAE
  • 12.6.3 Qatar
  • 12.6.4 South Africa
  • 12.6.5 Rest of Middle East & Africa

13 Key Developments

• 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 13.2 Acquisitions & Mergers
• 13.3 New Product Launch
• 13.4 Expansions
• 13.5 Other Key Strategies

14 Company Profiling

• 14.1 F. Hoffmann-La Roche Ltd.
• 14.2 Teva Pharmaceutical Industries Ltd.
• 14.3 Mylan N.V.
• 14.4 Pfizer Inc.
• 14.5 Novartis AG
• 14.6 GlaxoSmithKline plc
• 14.7 Merck & Co., Inc.
• 14.8 AstraZeneca
• 14.9 Aurobindo Pharma
• 14.10 Johnson & Johnson Private Limited
• 14.11 Cipla Inc.
• 14.12 Sun Pharmaceutical Industries Ltd.
• 14.13 Currax Pharmaceuticals LLC
• 14.14 Novo Nordisk A/S
• 14.15 Takeda Pharmaceutical Company Limited
• 14.16 Aristo Pharmaceuticals Ltd
• 14.17 Baxter International
• 14.18 Lupin Pharmaceuticals Inc.
• 14.19 Mankind Pharma
• 14.20 Macleods Pharmaceuticals Ltd